GC Cell Set to Participate in the US Cancer Moonshot Project
Initiative aims to reduce cancer mortality rates by 50% in the next 25 years.
GC Cell announced in a company press release that it will be joining CancerX, part of the US Cancer Moonshot project. Started by the Biden administration, the Cancer Moonshot aims to reduce cancer patient mortality rates by over 50% over the next 25 years. According to the company, it aims to highlight the importance and potential of cell therapy in cancer treatment through participating in the initiative.
"I am pleased to contribute to projects that can change the lives of many patients and their families,” said James Park, CEO, GC Cell.” “The Cancer Moonshot & CancerX provides an expanded opportunity to build diverse collaborative research and partnership frameworks with global companies."
Reference: GC Cell Joins US Cancer Moonshot Project. PR Newswire. October 24, 2023. Accessed October 25, 2023. https://www.prnewswire.com/news-releases/gc-cell-joins-us-cancer-moonshot-project-301966721.html
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
